Yearly Archives: 2020


Local News: Calculating the costs of beef production (2/19/20) – Monett Times

A panel of doctors of veterinary medicine attended the recent annual Beef Cattlemens Conference, hosted by the Monett Chamber of Commerce, the University of Missouri Extension and the Southwest Missouri Cattlemens Association, to discuss cattle health issues that can impact productivity and profit. From left, are: Dr. Ted Dahlstrom, of Monett; Dr. Darren Loula, of Clever; and Dr. Voyd Brown, of Cassville. Melonie Roberts/reporter@monett-times.com

The 51st annual Beef Cattlemens Conference, held Feb. 4 at the Monett National Guard Armory, posed some tough questions for producers attending the program.

One of the first topics, on calculating the cost of the operational costs for varying sizes of beef farms with a panel of successful producers, broke the costs of production down to a per cow basis.

Nathan Isakson, of Ash Grove, spoke of his beef cattle production at the 51st annual Beef Cattlemens Conference, hosted by the Monett Chamber of Commerce, the University of Missouri Extension and the Beef Cattlemens Association on Feb. 4, at the Monett National Guard Armory. Melonie Roberts/reporter@monett-times.com

Nathan Isakson, of Ash Grove, said he runs 2.5 head of cow-calf pair per acre on his farm, the majority of which is Show-Me Select, on a rotational basis.

We stockpile fescue for strip grazing from mid-November through the first week of February, Isakson said. We do feed hay in the event of snow or ice, because of trampling. We also feed hay through the month of September to allow the farm to rest for 30 days.

In lieu of building a barn, Isakson stores his tarped hay on a three-inch bed of gravel.

Cherry Warren, of Exeter, runs his Angus operation on 2,000 acres: 1,500 of which he owns and another 500 that he rents. Warren advised young producers to take care of the ground first, and the ground would, in turn, take care of the cattle. He also urged producers to precondition their cattle before taking them to the sale barn in January. Melonie Roberts/reporter@monett-times.com

Dont pay for a barn you never build, he said.

By using a scheduled plan of operation, grazing fertilized regrowth October through mid-November; feeding hay from February through April, Isakson said he has a higher percent of cows re-breeding faster, generating uniformity of calves at market time.

If we were able to graze through December without stockpiled forage, we would spend an additional $5,463 to provide the nutritional requirements of the herd, assuming a 750-pound [round] bale is valued at $40, he said. However, there is a difference in quality between lush fescue and baled hay.

Weaver Forest, of rural Verona, discussed how his Oleo Ranch because its one of the cheaper spreads, runs on a rotational grazing system. With 750 acres, Forest has practiced rotational grazing since 1966, and his advice to young farmers attending the 51st annual Beef Cattlemens Conference in Monett was, to have a supportive wife with a job off-farm, a good CPA, a good banker, and a good salesman. Mentor with other successful producers and learn what works for them. Melonie Roberts/reporter@monett-times.com

Isakson also advocates for soil testing, and fertilizes his fields based upon those test results.

Im a firm believer in dont guess, soil test, he said.

In accounting for the cost of feed, veterinary supplies, chemicals, veterinary labor, farm services, pasture rent, marketing fees and other expenses, Isakson said it costs him $589 per year per cow.

Weaver Forest, of rural Verona, said he follows a rotational grazing system on his 750-acre farm, and has since he started in the cattle business in 1966.

Ive used a number of different protocols, he said. Sometimes, you win. Sometimes, you lose. Thats the cattle business.

Forest said he had purchased most of his land since 1980.

But, I use pasture rent as an opportunity cost, he said.

Forest said he fertilizes his fields with chicken litter, but cautions young farmers.

Keep cattle off of mature fescue, he said.

Forest uses another practice that is not typically mentioned.

I have the vet pelvic measure every cow on the place, he said. Believe me, thats the cheapest $5 youll ever spend.

At the end of the season, when Forest calculates his operating costs, he estimates he invests $900 in each calf before it goes to market.

There are several things youll need to succeed in this business, he said. A supportive wife with a job off-farm, a good CPA, a good banker, and a good salesman. Mentor with other successful producers and learn what works for them.

The third panel member, Cherry Warren, of Exeter, said he operates his rotational grazing operation on 2,000 acres, 1,500 of which he owns and the remainder of which is leased.

I rotate the cows every two to three weeks, he said. It helps prevent fescue foot.

We calve both in the spring and in the fall. We background all calves. I keep about 100 heifers a year for replacements.

Warren attributed his success in his Angus cattle operation to his off-farm job of 18 years in the banking industry.

Thats where I learned about farming, he said. I talked with successful operators and learned from them.

Warren uses both chicken and turkey litter to fertilize his acreages.

Last summer, I couldnt put enough cattle on to eat the crab grass, he said. I do plant wheat as a cover crop, but fescue is still the main base.

In addition to making sure his cattle has plenty of lush fescue on which to graze, Warren also uses DNA testing results before buying a bull.

Those tests are more accurate, he said.

Upon calculating his annual costs of insurance, feed, fertilizer, vet costs, chemicals, wages, taxes fuel, utilities and supplies, Warren broke down his operational costs, based on a 90 percent calf crop, to $725 per calf.

Summing it up, Warren told younger producers why he doesnt mind aiding a laboring cow in the middle of a cold winter night.

We start calving in the fall and continue through January, he said. I dont mind it at all if I need to be out at midnight with a cow about to calve. I have a passion for cattle. Thats why I do this.

The next topic, the alternative protein market, was addressed by Dr. Byron Wiegand, a professor of animal science at University of Missouri in Columbia.

Wiegand noted there are a number of vegetable sources in todays marketplace by which people can meet their protein needs. However, there are some that are utilizing stem cells from inside a cows mouth, animal blood product, which is collected from a slaughterhouse, and grown in a lab.

They take satellite cells from a living animal and the product is proliferated in strips, to mimic skeletal muscle, he said. Its grown on a scaffold, instead of a skeletal structure, fed a nutrient-rich medium and then stretched for exercise, to achieve the texture of a meat product.

The product takes 21 days to mature in a bio-reactor, and there are guestimates that predict it will hit retail shelves by 2021.

The upside for local producers so far?

It costs $18,000 a pound to reproduce beef, he said. But [beef producers] will have competition when the technology catches up. What we dont know is if the marketing can catch up.

For those who believe that cultured meats will save the planet, Wiegand posed a reality check.

Cultured products are highly processed, which goes against the whole concept of clean labels and simple labels, he said. For example, the Impossible Burger, sold by Burger King, contains 19 ingredients to make it taste like meat. Meat only has one. And the Impossible Burger is $1 more expensive than the Whopper.

Weigand said many food processors, including Tyson Foods, Cargill and Archer Daniels Midland, have invested in the alternative meat industry.

Why? he asked. Because they want diversified portfolios; first-hand knowledge of the technology; secondary pick-up of brand loyalty; and millions in short-term revenue.

During his travels, Weigand ran into at least one individual who expressed his irritation with those trying to replicate a meat-flavored product to attract the vegetarian and vegan markets.

The man said he was aggravated that companies were doing this, he said. The guy told me he had willingly given up [meat], and did not see any reason behind companies trying to mimic a plant-based product targeted toward those who had made that choice.

Finally, Weigand questioned what agency or entity was going to be required to oversee the food safety aspect of cultured meat products.

Who is going to be responsible for ensuring the consumer is protected? he asked. That has not yet been determined.

Those issues, along with legislation that has not caught up with the technology, truth-in-labeling and other issues are currently working with local producers.

Right now, the motivation for companies is to make money from this process, Weigand said. That will take awhile.

Three doctors of veterinary medicine, Dr. Darren Loula, Dr. Ted Dahlstrom and Dr. Voyd Brown, rounded out the evenings presentation with a discussion on herd health.

Loula, of Clever, reported an increase in pink eye infection in cattle, citing flies, lack of shade and other contributors to the disease.

We now use a combination vaccinations, as well as talk to producers about other ways to reduce the potential for cattle to develop pink eye, he said.

Dahlstrom, Monett, spoke of the many benefits of using multi-strain vaccinations for herd health.

You have to give a booster after the initial0 pink eye vaccination, he said. It boosts protection from 65 to 95 percent. There is also a pink eye impact that contains the initial dose as well as the booster. It is highly successful, but a little inconvenient. You still have to use fly control. But we have the tools to enhance pink eye protection.

Loula also recommended producers take an hour to sit down with their veterinarian and develop a herd health plan.

Customers should tell their vet what they have been battling for the past couple of years, he said. We take that information and make a plan that works for you.

There has also been an increase in hairy heel warts in beef cattle.

Traditionally, this is more common to dairy herds, Loula said. However, our practice has a seen more cases in beef herds in the last few years.

The bacteria results in painful ulcerations and erosion of the heel of the foot, along with significant lameness.

Topical treatment is most effective, but keeping a clean environment and promoting a strong immune function in your herd is the best practice, he added.

Other suggestions included moving bale rings when the ground around them becomes muddy from weather and feces. The bacteria, which is highly contagious, thrives in damp dirty conditions, so keeping fields clean and minimizing cow contact with slurry reduces the risk of infection.

Dahlstrom said mycoplasma is not getting enough attention for current preventive practice strategies.

The bacteria is constantly mutating and changing, he said. It is an untreatable disease. Commonly used antibiotics do not work. They are a waste of time.

Mycoplasma has been classed as a highly contagious disease. The bacteria can cause a number of ailments to cattle, including mastitis in dairy cows, arthritis in cows and calves, pneumonia in calves, and various other diseases likely including late-term abortion.

The best thing you can do is take a bunch of calves to the back 40 and go back a couple of weeks later and pick up the live ones, he said. If your calves are sick, its already too late. There is no way to get them healthy.

Concerning open cows that did not become pregnant through natural methods or artificial insemination, Brown indicated economically, they are best culled from the herd.

She has to earn her spot on the farm, he said. If she has been a slow breeder the first time, shell be a slow breeder afterward.

When I am culling, if a cow has not produced that year, I get rid of her, Dahlstrom agreed. My wife will say, shes been a good cow, and has been is the key phrase. When you, the producer, are paying us to pregnancy check your cows, and one comes up open, they need a bus ticket. That is the way to stay ahead in the game.

Dahlstrom also noted that his practice also does vaccine compounding, using the right quantities of medications after cell culturing in his lab in Monett.

With the vaccinations we have made, we have identified 21 different strains of mycoplasma organisms, cultured from local farms, he said. The only way to know if your cattle have the same strain as your neighbors is to have them swabbed. These bugs mutate. They find a way to adapt to the environment and survive.

We have the tools you need, Brown said. You just have to implement and utilize those tools at the proper time in production.

See the original post:
Local News: Calculating the costs of beef production (2/19/20) - Monett Times

Searching for the ‘big break’ that could turn stem cells into a weapon against dementia – Genetic Literacy Project

Recent developments in the field of stem cell research are paving a path towards a radical shift in the way we diagnose and treat dementia. Stem cells have excited scientists for years and research groups across the globe are using them to advance modern medicine. Using stem cells to aid the fight against dementia is perhaps one of the most critical applications of the technology. Dementia is the leading cause of death in the UK, sixth in US and fifth globally, with an estimated 50 million people currently affected.

The term dementia does not relate to a single disease, but more an array of symptoms that can arise from multiple conditions. The most common is Alzheimers disease (AD) which accounts for up to 80% of all cases. Dementia itself is caused by the death of cells that make up the complex circuitry of our brains and an eventual loss of large portions of the brain. Patients suffering with dementia often exhibit the same general symptoms such as confusion, memory loss and an inability to perform day to day functions. It is a debilitating condition that often strikes the most vulnerable members of society and, consequently, many research groups around the globe work to try to understand dementia-causing diseases to provide better diagnostic and treatment platforms.

In 2007, a research group at Kyoto University in Japan published a study with the potential to change the face of research into dementia along with many other fields. Professor Shinya Yamanaka and his research team developed a method whereby stem cells (cells that can be transformed/differentiated into cells from any tissue) could be generated from a sample of skin. The study, which resulted in a 2012 Nobel Prize for Prof. Yamanaka, demonstrated that skin cells could be isolated from a patient and genetically reprogrammed into induced pluripotent stem cells (iPSCs). In short, this technology made it possible to generate and study brain cells from a patient with dementia without having to remove any of their brain. All they would need to do is provide scientists with a sample of skin.

Since this development, research groups around the globe have started using iPSCs from many patients with dementia in order to understand the biological mechanisms that underlie disease. Dr Eric Hill runs a research group at Aston University in the UK that specializes in iPSCs for dementia research and he had the following to say about the technology:

Its really exciting because it allows us to study cells with genetic mutations that are patient specific. We can get a much better picture of what is actually happening in the brains of these patients. We can now generate all the different cell types found in the human brain and understand how they function together and map the changes that result in disease.

The latter was perhaps most powerfully demonstrated in a study published by a team at the University of North Carolina, led by Professor Hansang Cho. The team was able to generate three key cell subtypes that play important roles in brain function; study the impact of mutations associated with Alzheimers disease; and even replicate some of the core malfunctions found to trigger disease in the brains of patients.

Studies like this are of significance because a large part of the focus in dementia research is on trying to understand how such changes in function arise. When a patient is diagnosed with a disease such as Alzheimers it is often too late for effective treatment. Scientists, instead, seek to elucidate those early changes in brain cell function in order to diagnose patients earlier to give more time for treatment. It is very much a case of prevention being better than a cure. Dr Hill provided an encouraging statement regarding this:

When we generate brain cells from iPSCs the cells we get are developmentally very young. What is interesting is the fact we still see differences between cells from dementia patients versus healthy patients suggesting we could find markers to help us detect and prevent disease some years before it develops.

Despite such promise, however, iPSCs have yet to provide the field of dementia research with that big break. Multiple treatments have progressed into clinical trials since the technology first emerged but no therapies have been approved. Drugs that show promise in the lab fail to deliver on their potential in patient clinical trials, sending researchers back to square one.

We should not be disheartened by this, however, and should instead view it as space into which the technology of using iPSCs to study dementia can grow. A lot of drugs fail in clinical trials because the platforms used to run initial tests dont provide scientists with a wide enough perspective of how those drugs will influence human cells. Additionally, many preclinical studies use animals with dementia-causing disease artificially induced into them. Studies like this often fail to translate into humans because the initial data is not from a human perspective. This is where researchers like Dr. Hill think iPSCs can provide us with an advantage:

iPSCs could provide us with much better platforms for screening drugs to treat and prevent these diseases. They can really add to what we already have, and while we might not be able to grow a full human brain, we can generate the cells that provide the building blocks for one. They give us the chance to screen new therapies more efficiently, better test their effectiveness and reduce the amount of animal use in dementia research.

Dr Hill is not alone in seeing the promise of using iPSCs to find better treatments for preventing the progression of dementia. Multiple research groups around the world have shown the potential of iPSC-derived brain cells for studying the effectiveness of new therapies.

In the last 12 months we have observed a wave of new studies using iPSCs to try to develop better treatments for diseases like Alzheimers, Parkinsons, Huntingtons disease and ALS. From studies in the University of California identifying cholesterol metabolism as a potential target to treating Alzheimers to studies in Luxembourg helping us find better treatments for Parkinsons, it is easy to see why the global effort to get that big break from iPSCs continues to gain interest. We might still be waiting for that next Noble Prize-winning discovery that will improve the lives of millions of patients but the collective effort of iPSC research groups across the world brings us a step closer with every study they publish. Dementia may, one day, be a thing of the past and iPSC research will likely be a significant part in getting us there.

Sam Moxon has a PhD in regenerative medicine and is currently involved in dementia research. He is a freelance writer with an interest in the development of new technologies to diagnose and treat degenerative diseases. Follow him on Twitter @DrSamMoxon

Link:
Searching for the 'big break' that could turn stem cells into a weapon against dementia - Genetic Literacy Project

Radiation, Inflammation and Triple-Negative Breast Cancer: A Study – OncoZine

Although radiation is successfully used to treat breast cancer, inflammation caused as a side-effect of radiation may have an adverse effect, promoting the survival of triple-negative breast cancer cells.

This is the conclusion of a study by Jennifer Sims-Mourtada, Ph.D., director of Translational Breast Cancer Research at ChristianaCares Helen F. Graham Cancer Center & Research Institute, published online in the International Journal of Radiation Biology.[1]

Triple-negative breast cancer is cancer that tests negative for estrogen receptors, progesterone receptors, and excess human epidermal growth factor receptor 2 (HER2) protein. As a result, the growth of this cancer is not fueled by the hormones estrogen and progesterone, or by the HER2 protein. These cancers tend to be more common in women under age 40, who are African-American, Latina, or who carry a mutated BRCA1 gene.

Triple-negative breast cancer accounts for 15-20% of all breast cancers and is faster growing than other types of breast cancers.

Sims-Mourtadas latest study helps scientists to better understand the mechanisms behind the development of this aggressive and hard-to-treat cancer. It shows that inflammation caused by radiation can trigger stem-cell-like characteristics in non-stem breast cancer cells.[1]

The good and the badThis is the good and the bad of radiation, Sims-Mourtada noted. We know radiation-induced inflammation can help the immune system to kill tumor cells thats good but also it can protect cancer stem cells in some cases, and thats bad.

Whats exciting about these findings is were learning more and more that the environment the tumor is in its microenvironment is very important. Historically, research has focused on the genetic defects in the tumor cells. Were now also looking at the larger microenvironment and its contribution to cancer, she added.

My work focuses on cancer stem cells and their origination. [These cells] exist in many cancers, but theyre particularly elusive in triple-negative breast cancer. Their abnormal growth capacity and survival mechanisms make them resistant to radiation and chemotherapy and help drive tumor growth, Sims-Mourtada explained.

The researchers applied radiation to triple-negative breast cancer stem cells and to non-stem cells. In both cases, they found radiation-induced an inflammatory response that activated the Il-6/Stat3 pathway, which plays a significant role in the growth and survival of cancer stem cells in triple-negative breast cancers. They also found that inhibiting STAT3 blocks the creation of cancer stem cells. As yet unclear is the role IL-6/STAT3 plays in transforming a non-stem cell to a stem-cell.

DelawareFor women living in Delaware, Sims-Mourtadas research is especially urgent: The rates of triple-negative breast cancer in the state are the highest nationwide.

At ChristianaCare, we are advancing cancer research to help people in our community today, while we also advance the fight against cancer nationwide, said Nicholas J. Petrelli, M.D., Bank of America endowed medical director of the Helen F. Graham Cancer Center & Research Institute.

Sims-Mourtadas research is a dramatic step toward better treatments for triple-negative breast cancer, Petrelli concluded.

To advance her research on inflammation, last year Sims-Mourtada received a US $ 659,538 grant from the Lisa Dean Moseley Foundation. The three-year grant will enable her and her team at the Cawley Center for Translational Cancer Research to continue investigating the role of cells immediately around a tumor in spurring the growth of triple-negative breast cancer and possible therapy for this particularly difficult to treat cancer.

Our next step is to understand the inflammatory response and how we might inhibit it to keep new cancer stem cells from developing, Sims-Mourtada said.

The researchers previously identified an anti-inflammatory drug, currently used to treat rheumatoid arthritis, that has the potential to target and inhibit the growth of cancer stem cells and triple-negative breast cancer tumors. That research could set the stage for clinical investigation of the drug, alone or in combination with chemotherapy, to improve outcomes for patients with triple-negative breast cancer.

Reference[1] Arnold KM, Opdenaker LM, Flynn NJ, Appeah DK, Sims-Mourtada J. Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells [published online ahead of print, 2020 Jan 6]. Int J Radiat Biol. 2020;114. doi:10.1080/09553002.2020.1705423 [Pubmed][Article]

See the original post here:
Radiation, Inflammation and Triple-Negative Breast Cancer: A Study - OncoZine

Novel Potential Combination Therapy for Childhood Brain Tumors – Technology Networks

Medulloblastoma, the most common brain cancer in children, may arise from biological abnormalities in neural stem cells or neuronal precursors during embryonic development. Indeed, the clinical challenges of treatment resistance and tumor recurrence in patients with medulloblastomas appear to be related to the presence of cancer stem cells within medulloblastoma tumors.Brazilian researchers working in the Cancer and Neurobiology Laboratory at the Federal University of Rio Grande do Sul (Universidade Federal do Rio Grande do Sul, UFRGS), its university hospital (Hospital de Clnicas de Porto Alegre, HCPA), and the Children's Cancer Institute (Instituto do Cncer Infantil, ICI) in Porto Alegre, in collaboration with Canadian scientists working at the Hospital for Sick Children and the University of Toronto, analyzed gene expression in medulloblastoma tumors from patients. They demonstrated that all medulloblastoma tumor subtypes express two stem cell markers, namely the proto-oncogene protein BMI1 and the cell surface protein CD133. When DNA is in a tightly compacted chromatin state, the expression of genes that promote cell differentiation is reduced, thereby keeping cancer cells in a stem cell-like state. Accordingly, this team of researchers treated medulloblastoma cells with an epigenetic compound that inhibits histone deacetylase (HDAC) activity, leading to chromatin relaxation, and found that they could thereby reduce BMI1 and CD133 expression and hinder tumor cell viability.

Further analysis of tumor samples revealed that expression of these "stemness" markers appeared to be associated with activity of the mitogen-activated protein kinase (MAPK)/ERK intracellular signaling pathway. To test the importance of MAPK/ERK signaling in carcinogenesis, the researchers examined the effects of inhibiting MAPK/ERK in medulloblastoma cells. They found that MAPK/ERK inhibition reduced the cellular content of stemness markers and decreased cancer stem cell formation in culture. Importantly, these antitumor effects were potentiated when the tumor cells were exposed to HDAC inhibitors and MAPK/ERK inhibitors at the same time.

According to the lead author of the article reporting these findings, Dr. Mariane da Cunha Jaeger, "these findings suggest that combining HDAC and MAPK/ERK inhibitors may be a novel and effective approach to preventing medulloblastoma cell proliferation by altering the tumor stem cell phenotype".

Professor Rafael Roesler, senior author of the study, underscores that this work demonstrates how "integrating gene expression data from patient tumors with cell culture experiments can enable the identification of novel potential therapy combinations".

Commenting on the research team's research outlook in light of these promising findings, the ICI Research Director Dr. Andr T. Brunetto has said, "We are focusing on finding translational opportunities that can be explored in innovative clinical studies on childhood cancers".ReferenceJaegar et al. (2020) HDAC and MAPK/ERK Inhibitors Cooperate To Reduce Viability and Stemness in Medulloblastoma. Journal of Molecular Neuroscience. DOI: https://doi.org/10.1007/s12031-020-01505-y

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read more:
Novel Potential Combination Therapy for Childhood Brain Tumors - Technology Networks

Stem Cell Therapy Market Size, Current Trends, Business Opportunities, Market Challenges and Analysis by 2026 – News Parents

The report carefully examines the Stem Cell Therapy Market, with a focus on most of the major players and their business strategies, geographical scope, market segments, product landscape and price and cost structure. Each section of the research study is specially prepared to investigate key aspects of the Stem Cell Therapy market. The area of market activity, for example, drivers, restrictions, trends and opportunities in the global market for Stem Cell Therapy is explored in detail. Through qualitative and quantitative analysis, we support you in a comprehensive and comprehensive analysis of the Stem Cell Therapy market. We also focus on the five forces analysis of SWOT, PESTLE and Porter in the Stem Cell Therapy market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Request a Sample Copy of this Report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=NPN&utm_medium=002

The main Companies operating in the Stem Cell Therapy Market are listed in the report.

Stem Cell Therapy Market: Competitive Landscape

The players who lead the Stem Cell Therapy market are analyzed taking into account their market share, the latest developments, new manufacturers, associations, acquisitions and markets. We also provide a comprehensive analysis of your product portfolio to explore the product and the applications that you focus on while operating in the Stem Cell Therapy market. In addition, the report offers two different market forecasts: one is the production side and the other on the use side of the Stem Cell Therapy market. It also provides practical advice for newcomers, as well as for established players in the world of smart camera market.

Stem Cell Therapy Market: Segment Analysis

This chapter focuses on the different segments in the Stem Cell Therapy market. The report segments the market by type, application, product, service and end user. This division enables a detailed view of the motif. It helps to understand the changes in production and the general needs of consumers that are likely to affect these segments.

Stem Cell Therapy Market: Regional Analysis

The chapter on regional analysis highlights the political scenario in emerging and industrialized countries that is expected to affect the dynamics of supply and demand. Regional analysis also helps identify the changing needs of the population that have a critical impact on the general market for Stem Cell Therapy . This part of the research report also took into account labor costs, raw materials and production costs by region.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=NPN&utm_medium=002

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market , By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market , By Solution

6.1 Overview

7 Stem Cell Therapy Market , By Vertical

7.1 Overview

8 Stem Cell Therapy Market , By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Request Report Customization @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=NPN&utm_medium=002

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Therapy Market Size, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis, Stem Cell Therapy Market Trends, Stem Cell Therapy Market

Here is the original post:
Stem Cell Therapy Market Size, Current Trends, Business Opportunities, Market Challenges and Analysis by 2026 - News Parents

Stem Cell Banking Market Globally Expected to Drive Growth through2017 2025 – Instant Tech News

TMRR, in its recent market report, suggests that the Stem Cell Banking market report is set to exceed US$ xx Mn/Bn by 2029. The report finds that the Stem Cell Banking market registered ~US$ xx Mn/Bn in 2018 and is spectated to grow at a healthy CAGR over the foreseeable period.

The Stem Cell Banking market research focuses on the market structure and various factors (positive and negative) affecting the growth of the market. The study encloses a precise evaluation of the Stem Cell Banking market, including growth rate, current scenario, and volume inflation prospects, on the basis of DROT and Porters Five Forces analyses. In addition, the Stem Cell Banking market study provides reliable and authentic projections regarding the technical jargon.

In this Stem Cell Banking market study, the following years are considered to project the market footprint:

The content of the Stem Cell Banking market report includes the following insights:

Request For Discount On This Report @ https://www.tmrresearch.com/sample/sample?flag=D&rep_id=6111&source=atm

On the basis of solution, the global Stem Cell Banking market report covers the following solutions:

Notable Developments

The need for improved regenerative medication and anatomy has played an integral role in driving fresh developments within the stem cell banking market.

Gallant has emerged as a notable market entity that has remained as the torchbearer of innovation within the global stem cell banking market. The company has recently launched stem cell banking for dogs, and has attracted the attention of the masses. As people become increasingly concerned about their pets, the new move by Gallant shall help the company in earning the trust of the consumers. Moreover, it can move several notches higher on the innovation index.

Cells4Life has also remained at the forefront of developments within the global stem cell banking market. After suffering backlash for its error in cord blood stem cell promotion, the company is expected to use effective public relation strategies to regain its value in the market.

Global Stem Cell Banking Market: Growth Drivers

Development of improved facilities for storage of stem cells has played an integral role in driving market demand. Furthermore, the unprecedented demand for improved analysis of regenerative medications has also created new opportunities within the global stem cell banking market. Medical research has attracted investments from global investors and stakeholders. The tremendous level of resilience shown by biological researchers to develop stem cell samples has aided market growth. Henceforth, the total volume of revenues within the global stem cell banking market is slated to multiply.

Commercialization of stem cell banks has emerged as matter of concern for the healthcare industry. However, this trend has also helped in easy storage and procurement of cells stored during the yester years of children. Presence of sound procedures to register at stem cell banks, and the safety offered by these entities, has generated fresh demand within the global market. New regional territories are opening to the idea of stem cell banking. Several factors are responsible for the growth of this trend. Primarily, improvements in stem cell banking can have favourable impact on the growth of the healthcare industry. Moreover, the opportunities for revenue generation associated with the development of functional stem cell banks has aided regional market growth.

The global stem cell banking market is segmented on the basis of:

Source

Request Sample Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6111&source=atm

The Stem Cell Banking market study answers critical questions including:

All the players running in the global Stem Cell Banking market are elaborated thoroughly in the Stem Cell Banking market report on the basis of R&D developments, distribution channels, industrial penetration, manufacturing processes, and revenue. In addition, the report examines, legal policies, and comparative analysis between the leading and emerging Stem Cell Banking market players.

Customize This Report @ https://www.tmrresearch.com/sample/sample?flag=CR&rep_id=6111&source=atm

Why choose TMRR?

Go here to read the rest:
Stem Cell Banking Market Globally Expected to Drive Growth through2017 2025 - Instant Tech News

Stem Cell Based Cell Therapies-Drug: Market Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2024 – Instant…

Stem Cell Based Cell Therapies-Drug Market Research Report 2020 This Report Is Comprised with Market Data Derived from Primary as Well As Secondary Research Techniques. The Points Covered in The Report Are Primarily Factors Which Are Considered to Be Market Driving Forces. The Report Aims to Deliver Premium Insights, Quality Data Figures and Information in Relevance with Aspects Such as Market Scope, Market Size, Market Share, Market Segments Including Types of Products and Services, Application Areas, Geographies As Well. It presents the 360-degree overview of the competitive landscape of the industries. SWOT analysis has been used to understand the Strength, Weaknesses, Opportunities, and threats in front of the businesses. Thus, helping the companies to understand the threats and challenges in front of the businesses. Stem Cell Based Cell Therapies-Drug Market is showing steady growth and CAGR is expected to improve during the forecast period.

The Stem Cell Based Cell Therapies-Drug Market Report Incorporates Valuable Differentiating Data Regarding Each of The Market Segments. These Segments Are Studied Further on Various Fronts Including Past Performance, Market Size Contributions, Market Share, Expected Rate of Growth, And More.

The Major Players in the Stem Cell Based Cell Therapies-Drug Market are Profiled in detail in View of Qualities and Share of The Overall Industry.TiGenix NVOrgenesisCESCA Therapeutics IncMesobalst LtdPluristem Therapeutics IncOCAtA Therapeutics Inc

Key Businesses Segmentation of Stem Cell Based Cell Therapies-Drug Market

Most important types of Stem Cell Based Cell Therapies-Drug products covered in this report are:Type 1Type 2Type 3Type 4Type 5

Most widely used downstream fields of Stem Cell Based Cell Therapies-Drug market covered in this report are:Application 1Application 2Application 3Application 4Application 5

In Conclusion, Stem Cell Based Cell Therapies-Drug Market Report Presents the Descriptive Analysis of the Parent Market Based On Elite Players, Present, Past and Futuristic Data Which Will Serve as A Profitable Guide for All the Stem Cell Based Cell Therapies-Drug Market Competitors.

Purchase FULL Report Now! https://www.qurateresearch.com/report/buy/HnM/global-stem-cell-based-cell-therapies-drug-industry/QBI-MR-HnM-517404

Major Players: The report provides company profiling for a decent number of leading players of the global Stem Cell Based Cell Therapies-Drug market. It brings to light their current and future market growth taking into consideration their price, gross margin, revenue, production, areas served, production sites, and other factors.

Industry Overview: The first section of the research study touches on an overview of the global Stem Cell Based Cell Therapies-Drug market, market status and outlook, and product scope. Additionally, it provides highlights of key segments of the global Stem Cell Based Cell Therapies-Drug market, i.e. regional, type, and application segments.

Stem Cell Based Cell Therapies-Drug Market Dynamics: The report shares important information on influence factors, market drivers, challenges, opportunities, and market trends as part of market dynamics.

Regional Market Analysis: It could be divided into two different sections: one for regional production analysis and the other for regional consumption analysis. Here, the analysts share gross margin, price, revenue, production, CAGR, and other factors that indicate the growth of all regional markets studied in the report.

Global Stem Cell Based Cell Therapies-Drug Market Forecast: Readers are provided with production and revenue forecasts for the global Stem Cell Based Cell Therapies-Drug market, production and consumption forecasts for regional markets, production, revenue, and price forecasts for the global Stem Cell Based Cell Therapies-Drug market by type, and consumption forecast for the global Stem Cell Based Cell Therapies-Drug market by application.

Stem Cell Based Cell Therapies-Drug Market Competition: In this section, the report provides information on competitive situation and trends including merger and acquisition and expansion, market shares of top three or five players, and market concentration rate. Readers could also be provided with production, revenue, and average price shares by manufacturers.

Contact Us:Web: http://www.qurateresearch.comE-mail: [emailprotected]Ph: US +13393375221, IN +919881074592

Qurate Business Intelligence delivers unique Market research solutions to its customers and help them to get equipped with refined information and Market insights derived from reports. We are committed to providing best business services and easy processes to get the same. Qurate Business Intelligence considers themselves as strategic partners of their customers and always shows the keen level of interest to deliver quality.

Read the original here:
Stem Cell Based Cell Therapies-Drug: Market Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2024 - Instant...

Global Cancer Therapies Market Forecast to Reach US$220.5 billion by 2025 – ResearchAndMarkets.com – Business Wire

DUBLIN--(BUSINESS WIRE)--The "Cancer Therapies - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global market for Cancer Therapies is projected to reach US$220.5 billion by 2025, driven by the rise in cancer prevalence to epidemic proportions and the still ongoing search to find effective treatments for the disease. Despite decades of research costing billions of dollars, a cure for cancer still remains elusive. This fact when juxtaposed with the epidemic spread of cancer will result in the disease emerging into the single most difficult to tackle public healthcare burden in the coming years. The pressure is therefore intensifying to research and develop newer and more effective therapies and treatment options. The reason why cancer is complex is due to its ability to continuously evolve and undergo molecular, genetic changes that affect behavior and response of tumor cells. Cancer cells evolve myriad ways to sabotage, stymie and trick the immune system preventing it from recognizing cancer cells, making the disease more resilient, aggressive and deadly. This has profound implications for the progression of the disease despite interventional therapies. Also, there are over 100 types of known cancer types. In addition the genetic diversity of tumors especially intra-tumor genetic heterogeneity makes finding a cure a challenge which the medical community continues to grapple with. Although the Cancer Genome Atlas (TCGA) has increased understanding of the diversity of cancer types, the disease continues to elude a cure while continuing to stretch the boundaries of medical science and understanding. Significant research is still required to understand the vast diversity of tumor gene expression, mutations and drug sensitivities.

Against the backdrop of tumor diversity, the universal 'one size fits all' therapy which is the current standard of care is primitive. Therapies like chemotherapy and radiation, although help increase survival rates are beset with side effects as they act as sledgehammers that destroy even healthy dividing cells at the cellular level. There is an urgent need for developing newer ways to target cancer's diversity and evolution. While a cure for cancer is unlikely, targeted therapies will witness huge gains for their better prognosis. Targeted therapies revolve around identifying major pathways responsible for the disease and its progression and administering specific drugs targeting these pathways. Targeted therapies have lower side effects and are more effective than conventional therapies. However, targeted therapy increases the risk of emergence of treatment-resistant phenotypes. As an antidote to this problem is the interest shed on combined therapy targeting, stem cell transplants, molecular targeted therapy, and nanotechnology. Will these emerging therapies offer new paradigms in cancer treatment in the future, is however a question which only time will answer. Nevertheless, new advancements being made infuse optimism.

For instance, scientists are close to identifying the key molecule involved in cancer's mix and match diversity and evolution. Dubbed as DHX8, the protein influences the fundamental process in a cell called 'alternative splicing'. Aberrations in alternative splicing are linked to cancer's progression and drug resistance. Drugs targeting the DHX8 Gene can likely help us find the elusive chink in cancer's biological armor allowing us to finally steal a march over this complex disease. An exciting future currently awaits cancer therapies through 2025 despite all the challenges involved. The United States and Europe represent large markets worldwide with a combined share of 68% of the market. China ranks as the fastest growing market with a CAGR of 11.2% over the analysis period supported by the massive strides taken by the country in developing affordable next-generation therapies. Aggressive reforms in drug regulations and approval mechanisms have helped China emerge into the second largest pharmaceutical industry worldwide.

Key Topics Covered:

I. Introduction, Methodology & Report Scope

II. Executive Summary

III. Market Analysis

IV. Competition

For more information about this report visit https://www.researchandmarkets.com/r/r0jl83

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Read the original post:
Global Cancer Therapies Market Forecast to Reach US$220.5 billion by 2025 - ResearchAndMarkets.com - Business Wire

Growing Demand for Personalized Medicine Will Drives the Humanized Mouse and Rat Model Market – Press Release – Digital Journal

The Humanized Mouse Model Market is projected to reach USD 128.9 Million, at a CAGR of 9.9% during the forecast period.

This press release was orginally distributed by SBWire

Northrook, IL -- (SBWIRE) -- 02/24/2020 -- The key factors propelling the growth of the market are the increasing number of research activities involving humanized models, growing demand for personalized medicine, an increasing number of R&D activities in pharmaceutical and biotechnology companies, and continuous support in the form of investments and grants from the government and private sectors. The objective of the report is to define, describe, and forecast the humanized mouse model market size based on type, application, end-user, and region.

According to the new market research report "Humanized Mouse and Rat Model Market by Type (Genetic, Cell-Based (CD34, PBMC, BLT)), Application (Neuroscience, Hematopoiesis, Oncology, Immunology & Infectious Diseases) & End User (Pharmaceutical & Biotechnology Companies, CRO)) - Global Forecast", published by MarketsandMarkets.

The Humanized Rat Model market is expected to reach USD 8.9 Million by 2022 from USD 5.9 Million in 2017, at a CAGR of 8.4% during the forecast period.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=131763955

Market Segmentation in Detailed:

Based on type, the market is segmented into a humanized mouse and humanized rat. The Humanized mouse model market is further segmented into a cell-based and genetic-based humanized mouse model. The genetic humanized mouse models segment accounted for the largest share of the market. The large share of this segment can be attributed to the wide use of genetic humanized mouse models in the analysis of compounds, biological efficacy and safety testing, the study of drug metabolism and disposition, and investigation of immune system development and function.

Based on application, the market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is expected to witness the highest growth, owing to the rising number of cancer research activities and increasing innovation to develop humanized mouse models tailored to meet the specific needs of cancer research.

Based on end-user, the market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The CROs segment is estimated to register the highest CAGR during the forecast period due to the growth in the number of pharmaceutical companies outsourcing their preclinical studies to CROs.

Worldwide Geographical Analysis:

The North American region is leading the humanized mouse models market is expected to account for the largest share of the market in 2017. Growth in this regional segment can primarily be attributed to growing biomedical research, preclinical activities by CROs and pharmaceutical R&D, continued and responsible use of animals ensured by animal care organizations, increasing monoclonal antibody production in the US along with growing stem cell research, and government support for the development of protein drugs in Canada

Request Research Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=131763955

Major Key Players Operating in Industry:

The Jackson Laboratory (US), Taconic Biosciences, Inc. (US), Horizon Discovery Group plc (UK), genOway, S.A. (France), Charles River Laboratories (US), Harbour Antibodies BV (China), Hera BioLabs (US), Vitalstar Biotechnology Co., Ltd. (China), inGenious Targeting Laboratory (US), AXENIS S.A.S (France), Crown Bioscience, Inc. (US), Transgenic, Inc. (Japan), and Champions Oncology, Inc. (US). The major players in the humanized rat models market include Horizon Discovery Group plc (UK), Hera BioLabs (US), and Yecuris Corporation (US).

For more information on this press release visit: http://www.sbwire.com/press-releases/release-1278836.htm

Read the original post:
Growing Demand for Personalized Medicine Will Drives the Humanized Mouse and Rat Model Market - Press Release - Digital Journal

Stem Cell Assay Market to Expand Substantially Owing to Technological Innovations During 2016 2024 – Instant Tech News

The latest study on the Stem Cell Assay market published by TMR offers a deep understanding of the various market dynamics such as the challenges, drivers, trends, and opportunities. The report further elaborates on the micro and macro-economic factors that are expected to shape the growth of the Stem Cell Assay market during the forecast period (2019-2029).

The presented study elucidates the key indicators of market growth that includes a thorough analysis of the value chain, CAGR growth, and Porters Five Forces Analysis. This data will enable readers to understand the quantitative growth parameters of the global Stem Cell Assay market.

This Stem Cell Assay market report forecasts revenue growth at global, regional & country levels and provides an analysis on the industry trends in each of the sub-segments from 2019 to 2029. For the purpose of this study, TMR has segmented the global Stem Cell Assay market on the basis of product, application, and region:

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=19364

After reading the Stem Cell Assay market report, readers can:

Analytical Insights Included in the Report

Stem Cell Assay Market Segmentation Assessment

The growth prospects of the Stem Cell Assay market in various regions are thoroughly analyzed in the report along with vital information such as the regulatory framework, political, and economic outlook of each region.

Critical Insights enclosed from this report:

Market segments and sub-segments

The regional analysis covers:

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

Note:Although care has been taken to maintain the highest levels of accuracy in TMRs reports, recent market/vendor-specific changes may take time to reflect in the analysis.

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=19364

The Stem Cell Assay market report focuses on major growth trajectories such as drivers, restraints, challenges and opportunities that will have a significant impact on the incontinence devices market growth in the forecast duration. Besides this, the report lists various segments of the market and the competitive landscape of the market with base and forecast figures and the estimated CAGRs. Adding to that, the list of significant players and their plan of action for drawing better revenues is available in the report. Furthermore, key industry developments and interesting insights into the market, along with current incontinence devices market trends, are also provided in the report.

The report aims to resolve the following doubts related to the Stem Cell Assay market:

Reasons to Choose TMR:

About TMR

TMR is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, TMR employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact:

TMR

State Tower,

90 State Street,

Suite 700,

Albany NY 12207

United States

USA Canada Toll Free: 866-552-3453

View original post here:
Stem Cell Assay Market to Expand Substantially Owing to Technological Innovations During 2016 2024 - Instant Tech News